Products for Research Use Only
RegisterLogin

Firocoxib

CAT: 0804-HY-14670-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14670-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM) . Firocoxib has anti-inflammatory effects[1].
CAS Number
189954-96-9
Product Name Alternative
ML 1785713
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
COX
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Firocoxib.html
Concentration
10mM
Purity
99.54
Solubility
DMSO : ≥ 52 mg/mL
Smiles
O=C1OC(C)(C)C(C2=CC=C(S(=O)(C)=O)C=C2)=C1OCC3CC3
Molecular Formula
C17H20O5S
Molecular Weight
336.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Steagall PV, et al. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007 Jun;30 (3) :218-23.|[2]Stock ML, et al. Pharmacokinetics of firocoxib in preweaned calves after oral and intravenous administration. J Vet Pharmacol Ther. 2014 Oct;37 (5) :457-63.|[3]Albanese F, et al. Clinical outcome and cyclo-oxygenase-2 expression in five dogs with solar dermatitis/actinic keratosis treated with firocoxib. Vet Dermatol. 2013 Dec;24 (6) :606-12, e147.|[4][1].McCann ME, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am J Vet Res. 2005 Jul;66 (7) :1278-84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
COX-1; COX-2

Alternative Products

CatalogName
B4807-5Firocoxib
MBS6054513-01Firocoxib-d4

Popular Products